漢康生技 - HanchorBio - 創新、卓越、高效

創新驅動生命希望照亮未來

Innovating for Life, Inspiring Hope

Our Possibility

我們的可能性

研發專案

                                                                8
                                +
                            

專利申請

                                                                100
                                +
                            

進入臨床IND階段

最快

                                                                2.3
                                年
                            

2024年的研發投資金額

                                                                7.89
                                億元
                            

FBDB™

技術平台的核心優勢

結合先天性及適應性免疫系統多管齊下攻擊腫瘤細胞
阻斷 SIRPα / CD47 訊號傳遞
阻斷 PD-1 / PD-L1訊號傳遞
改善腫瘤微環境或進一步激活巨噬細胞/T細胞

更多核心技術

News

最新消息

HCB101-Shows-Clean- Cytopenia-Sparing-Safety

HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

HanchorBio Announces Oral Presentation of HCB101 at the […]

12 月 12, 2025

【Meeting Preview】HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

HanchorBio Announces Oral Presentation of HCB101 at the […]

12 月 10, 2025

$HanchorBio-Presents-First-In-Human-Data-Of-HCB101-Monotherapy-In-Relapsed-Refractory-Non-Hodgkin-Lymphoma-At-ASH-2025$

HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 漢康生技於 2025 年美國血液學會（ASH）年會發表 HCB101 單藥治療人體試驗結果

HanchorBio Presents First-in-Human Data of HCB101 Monot […]

12 月 09, 2025

$HanchorBio-Presents-First In Human-Data-Of-HCB101-Monotherapy-In-Relapsed-Refractory-Non-Hodgkin-Lymphoma-At-ASH-2025$

【Meeting Preview】HanchorBio Presents First-in-Human Phase 1 Data of HCB101 at the 67th American Society of Hematology (ASH) Annual Meeting 漢康生技於第 67 屆美國血液學會（ASH）年會公布 HCB101 I 期臨床數據

HanchorBio Presents First-in-Human Phase 1 Data of HCB1 […]

12 月 03, 2025

漢康生技三靶點融合蛋白HCB301完成兩個劑量組安全性評估　全球臨床推進再跨一步

漢康生技（HanchorBio, KY-7827）宣布，其以自主 FBDB™ 多功能融合蛋白平台開發的三靶點創新藥 HCB301，已完成臨床一期前兩個劑量組安全性觀察，結果顯示耐受性良好，具臨床開發潛力。HCB301 兼具阻斷 SIRPα-CD47、PD-1/PD-L1 及 TGFβ 三大機制，能同時啟動先天與適應性免疫、克服腫瘤免疫抑制，為難治型癌症帶來新療法。該試驗（NCT06487624）正於中美兩地進行，台灣審查中，顯示漢康在免疫融合蛋白領域的全球開發邁出重要一步。

11 月 11, 2025

HanchorBio Presents Preclinical Data at the SITC 2025 on HCB301, a First-in-Class Tri-Specific Immunotherapy Targeting SIRPα-CD47, PD-1/PDL1, and TGFβ 漢康生技在SITC 2025公佈HCB301臨床前資料首創三特異性免疫療法靶向SIRPα-CD47、PD-1/PD-L1和TGFβ

Novel fusion protein shows potent macrophage activation […]

11 月 06, 2025

漢康HCB101再現臨床突破　頭頸癌試驗起始低劑量組患者2/2出現腫瘤大幅縮小

全球臨床階段生技公司漢康生技（7827）宣布，旗下免疫治療新藥HCB101在臨床試驗中再度傳來捷報。繼二線胃癌 […]

10 月 30, 2025

漢康HCB101二線胃癌最新數據亮眼　近九成患者腫瘤顯著縮小

全球臨床階段生技公司漢康生技（7827）公布旗下免疫治療新藥 HCB101 的最新臨床試驗數據，顯示該藥在晚期 […]

10 月 29, 2025

HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology 漢康研發團隊再傳喜訊，融合蛋白藥物榮登頂尖腫瘤學期刊

Prestigious peer-review validates HCB101’s differ […]

10 月 23, 2025

HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation

HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.

10 月 08, 2025